Alkermes applies its scientific expertise and technological know-how to develop innovative medicines designed to help patients with serious, chronic conditions better manage their disease.
Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference Read More
Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program Read More
Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference Read More